Iterum Therapeutics (NASDAQ:ITRM) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report report published on Tuesday, Benzinga reports. They currently have a $5.00 target price on the stock.

Iterum Therapeutics Stock Down 12.0 %

Shares of Iterum Therapeutics stock opened at $0.95 on Tuesday. Iterum Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.50. The business’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.37. The firm has a market cap of $15.73 million, a PE ratio of -0.36 and a beta of 2.26.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.22. Equities research analysts anticipate that Iterum Therapeutics will post -1.19 EPS for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.